I would recommend you to join a study.-Cynthia, Study Participant
I do recommend this research group!-Rosie, Study Participant
Really Enjoyed meeting everyone here.-Alex, Study Participant
ALL of you are great.-Jolene, Study Participant
and I would definitely like to collaborate with your site on future trials. I sincerely appreciate all of the efforts made to date on our studies!
They are very considerate to make every effort to make me comfortable.-Ralph, Study Participant
very helpful staff.
Everyone is aware of their responsibilities, knowledgeable of research and very cooperative. The entire organization is well run from the top down. This is my favorite site to work with!
They explain all procedures and why. The staff is courteous and friendly and they listen. They ask often if you need anything, are friendly and smiling. A smile always goes a long way, even when you don’t feel like smiling.-Diane, Study Participant
Good job, keep up the good work.
Happy to be
part of this study; will recommend this clinic to others!
and requests for study questions. Staff at the site is very friendly and accommodating. Patients' charts are very well organized and complete
Everyone is so friendly each time I have an appointment.-Gloria, Study Participant
I never felt I was in a doctor’s office; it felt like being at home.
Principal Investigator was available to meet and showed oversight in source. Data and regulatory binders were clean and well maintained.
Very willing to make the testing sessions as comfortable as if one is at home. The staff treats me with care, compassion and understanding.-Mary Ann, Study Participant
and pays attention to detail. Data corrections are usually handled quickly. All staff seem organized and are conscientious about their work.-Sanofi Monitor
as well as the study performance. A combination of professional and a concerned family.-Michael, Study Participant
April 15, 2015...In this month’s issue of The Journal of Allergy and Clinical Immunology, Dr. Robert Jacobs, a Principal Investigator for the Biogenics Research Chamber, is the first author of “Symptom Dynamics During Repeated Serial Allergen Exposures to House Dust Mite.” Allergy to house dust mite is the most common allergy that causes nasal and eye symptoms. Exposure to house dust mite is also a risk factor for developing asthma. Because the mite is present in most homes and buildings, it is very difficult to study targeted treatments for the allergy in natural settings. The antigen challenge chamber provides consistent selected antigen exposure to a group of allergic participants involved in studies of therapies for allergic symptoms. In this longitudinal study, performed in conjunction with Dr. Sunil Ahuja and his team from the University of Texas Health Science Center in San Antonio, exposure to dust mite caused major nasal and eye symptoms in allergic persons while non-allergic control persons experienced minimal symptoms. Exposures were performed for three hours at a time over a four day period. After a 38 day observation phase, the four day exposures were repeated. Symptoms during the two sets of exposures over four days each were comparable, suggesting that this model of dust mite allergy can be successfully utilized to study therapeutic benefits of both medications and vaccines targeting this allergy.
About the Company:
Biogenics Research Chamber located in San Antonio, Texas has the only large permanent pollen exposure testing facilities in the United States. Dr. Robert Jacobs, Dr. Daniel Ramirez and Dr. Charles Andrews are the owners and Principal Investigators. The two separate facilities each have large chambers capable of testing up to 60 allergic participants at a time and also moderate sized chambers for specialty testing. All four chambers utilize unique engineering and antigen delivery systems. Compared to natural seasonal and perennial allergy studies, the chambers offer controlled conditions without pollen or antigen concentration variation and weather interruptions. Proof of concept, dose-ranging, and onset of action studies are performed for pharmaceutical and vaccine trials.